A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury

Uwe Hoff, Gordana Bubalo, Mandy Fechner, Maximilian Blum, Ye Zhu, Andreas Pohlmann, Jan Hentschel, Karen Arakelyan, Erdmann Seeliger, Bert Flemming, Dennis Gürgen, Michael Rothe, Thoralf Niendorf, Vijaya L. Manthati, J R Falck, Michael Haase, Wolf Hagen Schunck, Duska Dragun

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. Methods: Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI. Results: Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. Conclusions: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.

Original languageEnglish (US)
Article numbere13297
JournalActa Physiologica
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acute Kidney Injury
Eicosanoids
Acids
Ischemia
Cytochrome P-450 Enzyme System
Reperfusion
Kidney
Glycogen Synthase Kinase 3
Nephrectomy
Phosphatidylinositol 3-Kinases
Constriction
Individuality
Thoracic Surgery
Creatinine
Pharmacology
20-hydroxy-5,8,11,14-eicosatetraenoic acid

Keywords

  • acute kidney injury
  • CYP-eicosanoids
  • inflammation
  • reoxygenation
  • signalling

ASJC Scopus subject areas

  • Physiology

Cite this

Hoff, U., Bubalo, G., Fechner, M., Blum, M., Zhu, Y., Pohlmann, A., ... Dragun, D. (2019). A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury. Acta Physiologica, [e13297]. https://doi.org/10.1111/apha.13297

A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury. / Hoff, Uwe; Bubalo, Gordana; Fechner, Mandy; Blum, Maximilian; Zhu, Ye; Pohlmann, Andreas; Hentschel, Jan; Arakelyan, Karen; Seeliger, Erdmann; Flemming, Bert; Gürgen, Dennis; Rothe, Michael; Niendorf, Thoralf; Manthati, Vijaya L.; Falck, J R; Haase, Michael; Schunck, Wolf Hagen; Dragun, Duska.

In: Acta Physiologica, 01.01.2019.

Research output: Contribution to journalArticle

Hoff, U, Bubalo, G, Fechner, M, Blum, M, Zhu, Y, Pohlmann, A, Hentschel, J, Arakelyan, K, Seeliger, E, Flemming, B, Gürgen, D, Rothe, M, Niendorf, T, Manthati, VL, Falck, JR, Haase, M, Schunck, WH & Dragun, D 2019, 'A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury', Acta Physiologica. https://doi.org/10.1111/apha.13297
Hoff, Uwe ; Bubalo, Gordana ; Fechner, Mandy ; Blum, Maximilian ; Zhu, Ye ; Pohlmann, Andreas ; Hentschel, Jan ; Arakelyan, Karen ; Seeliger, Erdmann ; Flemming, Bert ; Gürgen, Dennis ; Rothe, Michael ; Niendorf, Thoralf ; Manthati, Vijaya L. ; Falck, J R ; Haase, Michael ; Schunck, Wolf Hagen ; Dragun, Duska. / A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury. In: Acta Physiologica. 2019.
@article{8caa7ea3d4864c21a1f0e221e27e46fa,
title = "A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury",
abstract = "Aim: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. Methods: Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI. Results: Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. Conclusions: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.",
keywords = "acute kidney injury, CYP-eicosanoids, inflammation, reoxygenation, signalling",
author = "Uwe Hoff and Gordana Bubalo and Mandy Fechner and Maximilian Blum and Ye Zhu and Andreas Pohlmann and Jan Hentschel and Karen Arakelyan and Erdmann Seeliger and Bert Flemming and Dennis G{\"u}rgen and Michael Rothe and Thoralf Niendorf and Manthati, {Vijaya L.} and Falck, {J R} and Michael Haase and Schunck, {Wolf Hagen} and Duska Dragun",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/apha.13297",
language = "English (US)",
journal = "Skandinavisches Archiv F{\"u}r Physiologie",
issn = "0370-839X",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury

AU - Hoff, Uwe

AU - Bubalo, Gordana

AU - Fechner, Mandy

AU - Blum, Maximilian

AU - Zhu, Ye

AU - Pohlmann, Andreas

AU - Hentschel, Jan

AU - Arakelyan, Karen

AU - Seeliger, Erdmann

AU - Flemming, Bert

AU - Gürgen, Dennis

AU - Rothe, Michael

AU - Niendorf, Thoralf

AU - Manthati, Vijaya L.

AU - Falck, J R

AU - Haase, Michael

AU - Schunck, Wolf Hagen

AU - Dragun, Duska

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. Methods: Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI. Results: Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. Conclusions: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.

AB - Aim: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. Methods: Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI. Results: Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. Conclusions: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.

KW - acute kidney injury

KW - CYP-eicosanoids

KW - inflammation

KW - reoxygenation

KW - signalling

UR - http://www.scopus.com/inward/record.url?scp=85067069670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067069670&partnerID=8YFLogxK

U2 - 10.1111/apha.13297

DO - 10.1111/apha.13297

M3 - Article

C2 - 31077555

AN - SCOPUS:85067069670

JO - Skandinavisches Archiv Für Physiologie

JF - Skandinavisches Archiv Für Physiologie

SN - 0370-839X

M1 - e13297

ER -